Episode Details

Moderna and Merck just dropped a game-changer in melanoma treatment: a personalized mRNA vaccine that slashes recurrence risk by 44% when paired with Keytruda. By sequencing tumors to target 34 unique mutations, the vaccine trains your immune system to hunt cancer cells—offering new hope for high-risk patients. While side effects exist, early results are so promising doctors are already eyeing applications across other cancers. This isn’t sci-fi—it’s the next frontier in precision oncology.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/0a8c36c00f1b730c